Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13109452 | 0.83 | LMNA (0.45) | LMNATHRB | |
| SCHEMBL3315106 | 0.81 | — | — | |
| SCHEMBL18106104 | 0.79 | OPRM1 (0.52) | LMNATHRB | |
| SCHEMBL610212 | 0.79 | OPRM1 (0.52) | LMNATHRB | |
| SCHEMBL10151514 | 0.79 | LMNA (0.43) | LMNATHRBBLM | |
| SCHEMBL24090459 | 0.77 | OPRM1 (0.50) | LMNATHRB | |
| SCHEMBL3317092 | 0.77 | OPRM1 (0.50) | LMNATHRB | |
| SCHEMBL5538153 | 0.77 | OPRM1 (0.50) | LMNATHRB | |
| SCHEMBL22649557 | 0.77 | OPRM1 (0.50) | LMNATHRB | |
| SCHEMBL471924 | 0.77 | OPRM1 (0.50) | LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9877966-B1 | Combination therapy for the inhibition of metastasis and tumorigenesis | OLIVA EUGENE J (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-14 | — | — | US | disclosed |
| US-9663521-B2 | Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-05-30 | — | — | US | disclosed |
| US-9603895-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9156886-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | NORTHWESTERN UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| US-20130183267-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8367618-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8088725-B2 | Fragrance compositions and compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-8088725-B2 | Fragrance compositions and compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2012-01-03 | — | — | US | disclosed |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20100132249-A1 | Fragrance Compositions and Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
| US-20100132249-A1 | Fragrance Compositions and Compounds | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
| WO-2008092678-A2 | FRAGRANCE COMPOSITIONS AND COMPOUNDS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-08-07 | — | — | WO | disclosed |
| WO-2005100301-A1 | 2-ARYLOXYETHYL GLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-10-27 | — | — | WO | disclosed |
| EP-0276124-B1 | PROSTAGLANDIN DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE | Sankyo Company Limited (JP) | 1992-05-20 | — | — | EP | disclosed |
| US-4981872-A | ANTIULCER | SANKYO COMPANY LIMITED (JP) | 1991-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323438-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | LMNA 424/4885THRB 2154/4885BLM 1758/4885 |
| US-20130183267-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, PTPRC | LMNA 3948/4885THRB 4779/4885BLM 4239/4885 |
| US-20170260192-A1 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS | PGF, BRCA1, RB1 | LMNA 424/4885THRB 2154/4885BLM 1758/4885 |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, PTPRC | LMNA 3948/4885THRB 4779/4885BLM 4239/4885 |
| US-20100132249-A1 | Fragrance Compositions and Compounds | H1-0, H1-10, H1-5 | LMNA 2425/4885THRB 4160/4885BLM 2352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.